CYP24A1 is overexpressed in keloid keratinocytes and its inhibition alters profibrotic gene expression
Open Access
- 2 January 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in Burns & Trauma
- Vol. 13, tkae063
Abstract
Background: Keloids are disfiguring, fibrotic scar-like lesions that are challenging to treat and commonly recur after therapy. A deeper understanding of the mechanisms driving keloid formation is necessary for the development of more effective therapies. Reduced vitamin D receptor (VDR) expression has been observed in keloids, implicating vitamin D signaling in keloid pathology. Vitamin D exhibits anti-proliferative and anti-inflammatory properties, suggesting it could have therapeutic utility in keloid disorder. The current study investigated vitamin D-regulated gene expression in keloid keratinocytes and the effects of inhibiting an enzyme involved in vitamin D metabolism on the phenotype of keloid-derived keratinocytes. Methods: Normal and keloid-derived primary keratinocytes were isolated from normal skin and keloid lesions, respectively, and were cultured in the absence or presence of vitamin D. In some experiments, inhibitors of the vitamin D metabolizing enzyme CYP24A1, ketoconazole or VID400 were added in the absence or presence of vitamin D. Cellular proliferation, migration and gene expression were measured. Results: We observed significant overexpression of CYP24A1 mRNA in keloid versus normal keratinocytes and increased CYP24A1 protein levels in keloids versus normal skin. CYP24A1 encodes 24 hydroxylase and is induced by vitamin D in a feedback loop that regulates vitamin D levels; thus, inhibition of CYP24A1 activity may locally increase active vitamin D levels. Ketoconazole, a non-specific cytochrome P-450 inhibitor, reduced proliferation of keloid and normal keratinocytes, but VID400, a specific CYP24A1 inhibitor, only significantly affected keloid keratinocyte proliferation. Neither inhibitor significantly reduced keratinocyte migration. The two inhibitors had different effects on vitamin D target gene expression in keratinocytes. Specifically, ketoconazole treatment reduced CYP24A1 expression in normal and keloid keratinocytes, whereas VID400 increased CYP24A1 expression. Both inhibitors decreased expression of profibrotic genes, including periostin and hyaluronan synthase 2, in keloid-derived cells. Combined treatment of keloid keratinocytes with vitamin D and ketoconazole or VID400 increased the effects of vitamin D treatment on target genes, although the effects were gene- and cell type-specific. Conclusions: The data suggest that reduction of vitamin D inactivation with CYP24A1 inhibitors may reduce profibrotic gene expression in keloid-derived cells. Therefore, CYP24A1 inhibitors may serve as adjunctive therapies to suppress keloid-associated gene expression changes.Keywords
Funding Information
- Shriners Children’s (72005-CIN-21)
This publication has 81 references indexed in Scilit:
- The Mechanism of 1,25-Dihydroxyvitamin D3Autoregulation in KeratinocytesJournal of Biological Chemistry, 2002
- Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike mannerAmerican Journal of Physiology-Cell Physiology, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Cross-talk between 1,25-Dihydroxyvitamin D3 and Transforming Growth Factor-β Signaling Requires Binding of VDR and Smad3 Proteins to Their Cognate DNA Recognition ElementsJournal of Biological Chemistry, 2001
- Selective inhibition of vitamin D hydroxylases in human keratinocytes11Abbreviations: VD: vitamin D3; 25(OH)D3: 25-hydroxyvitamin D3; 3H-25(OH)D3: [26,27n-3H] 25-hydroxyvitamin D3; 1α,25(OH)2D3: 1α,25-dihydroxyvitamin D3; 1α,25(OH)2-3epi-D3: 1α,25-dihydroxyvitamin-3-epi-D3; 1α,24(R),25(OH)3D3: 1α,24(R),25-trihydroxyvitamin D3, 1α,25(OH)2-24oxo-D3: 1α,25-dihydroxy-24oxo-vitamin D3; 1α,23(S),25(OH)3-24oxo-D3: 1α,23(S),25-trihydroxy-24oxo-vitamin D3; calcitroic acid: 1α-hydroxy-23-carboxy-24,25,26,27-tetranorvitamin D3; CYP: cytochrome P450; 1α-hydroxylase: 25-hydroxyvitamin D3-1α-hydroxylase; 24-hydroxylase (CYP24), 1α,25-hydroxyvitamin D3-24-hydroxylase; PHK, primary human keratinocytes; KGM: keratinocyte growth medium; HPLC, high performance liquid chromatography; IC50: half-maximum inhibitor concentration; SD: standard deviation.Steroids, 2001
- 1,25-Dihydroxyvitamin D3Increases Nuclear Vitamin D3Receptors by Blocking Ubiquitin/Proteasome-Mediated Degradation in Human SkinMolecular Endocrinology, 1999
- Distinct, Tissue-Specific Regulation of Vitamin D Receptor in the Intestine, Kidney, and Skin by Dietary Calcium and Vitamin DEndocrinology, 1998
- The Retinoid X Receptor Agonist 9-cis-Retinoic Acid and the 24-Hydroxylase Inhibitor Ketoconazole Increase Activity of 1,25-Dihydroxyvitamin D3 in Human Skin In VivoJournal of Investigative Dermatology, 1997
- Racial Pigmentation and the Cutaneous Synthesis of Vitamin DArchives of Dermatology, 1991
- Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cellsArchives of Biochemistry and Biophysics, 1989